🇺🇸 FDA

Intelligence · Patent portfolio

Teva Pharma Patents

Full USPTO pharma patent portfolio for Teva Pharma — grant dates, expiration, and drug cross-links.

Patents
454
Expiring ≤24m
49

Quick answer

Teva Pharma has 454 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 49 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 10

  1. US 10188811

    Nasal spray device

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10130621

    Analogs of pridopidine, their preparation and use

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10035802

    Solid state forms of ibrutinib

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10034866

    Inhalable medicament comprising tiotropium

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9980904

    Dry powder formulation

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9963515

    Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9951017

    S1P3 antagonists

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9896502

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9890211

    Antagonist antibodies directed against calcitonin gene-related peptide

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9890210

    Antagonist antibodies directed against calcitonin gene-related peptide

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9884907

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9884908

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9814706

    Hydrobromide salt of pridopidine

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9796673

    L-tartrate salt of pridopidine

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9763993

    Process for manufacturing glatiramer acetate product

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9763904

    Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9707295

    Inhalable medicament

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9702007

    Genetic markers predictive of response to glatiramer acetate

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9682033

    Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9662322

    Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9655969

    Inhalable medicament comprising tiotropium

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9636334

    Combination of lenalidomide and polypeptide construct, and uses thereof

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9625473

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9617596

    Biomarkers predictive for clinical response for glatiramer acetate

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9611322

    Fusions of antibodies to CD38 and attenuated interferon alpha

    Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9592291

    Methods for iontophoretically treating nausea and migraine

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9585878

    Treatment of BDNF-related disorders using laquinimod

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9505826

    Modified antibody with improved half-life

    Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9499868

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9427578

    Pharmacokinetics of iontophoretic sumatriptan administration

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9415008

    Dry powder inhaler

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9409662

    Formulations of albu-BChE, preparation and uses thereof

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9382200

    Process for the preparation of and crystalline forms of optical enantiomers of modafinil

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9375403

    Formulations of 6-mercaptopurine

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9364540

    Inhalable medicament

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9346746

    R(+)-N-formyl-propargyl-aminoindan

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9339469

    R(+)-N-methyl-propargyl-aminoindan

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9340307

    Stable laquinimod preparations

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9308182

    Parenteral formulations of rasagiline

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9284276

    N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof

    Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9272137

    Transdermal methods and systems for the delivery of anti-migraine compounds

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9233927

    Crystals of laquinimod sodium and improved process for the manufacture thereof

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9220692

    Methods of reducing symptoms in subjects using single dosage forms with tapering release rates

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9186333

    Process for preparing pharmaceutical compositions of fingolimod

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9180097

    Formulations of 6-mercaptopurine

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9161936

    Laquinimod for treatment of GABA mediated disorders

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9161935

    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Teva Pharma have?

454 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Teva Pharma patents expire?

49 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.